Deep Track Capital’s Apogee Therapeutics APGE Stock Holding History

Deep Track Capital’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24M	Buy	+285,000	New	+$20.7M	0.39%	50
2024 Q4	–	Sell	-1,000,000	Closed	-$58.7M	–	66
2024 Q3	$58.7M	Hold	1,000,000	–	–	1.86%	20
2024 Q2	$39.4M	Sell	1,000,000 -1,323,456	-57%	-$64.2M	1.17%	33
2024 Q1	$154M	Hold	2,323,456	–	–	4.42%	3
2023 Q4	$64.9M	Sell	2,323,456 -90,917	-4%	-$1.82M	2.17%	16
2023 Q3	$51.4M	Buy	+2,414,373	New	+$53.2M	1.98%	19

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Deep Track Capital's APGE Position: Q1 2026 in Review

Deep Track Capital opened a new position in Apogee Therapeutics (APGE) in Q1 2026: 285,000 shares worth $24M. The stake represents 0.39% of the portfolio and ranks #50 among its holdings. This is a return to the name: Deep Track Capital previously reported a position in APGE as recently as Q3 2024.

Deep Track Capital first reported a position in APGE in Q3 2023 and has held it in 6 quarters since. The position peaked at $154M in Q1 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

Deep Track Capital held 285,000 shares of Apogee Therapeutics worth $24M as of Q1 2026.
Apogee Therapeutics was a new Deep Track Capital position in Q1 2026.
Apogee Therapeutics made up 0.39% of Deep Track Capital's portfolio in Q1 2026, its #50 holding.
Deep Track Capital first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 6 quarters since.
Deep Track Capital's Apogee Therapeutics position peaked at $154M in Q1 2024.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.